Bayer Portugal entering a new era, with four new medicines hitting the national market

May 20, 2013 | By Márcio Barra

Diário Economico ran today an interview with the Managing Director of Bayer’s Portugal, Nelson Ambrogio, where Bayer’s growing national portfolio was highlighted as being responsible for bringing of a new era for the Portuguese subsidiary.

Bayer Portugal Managing Director, Nelson Ambrogio

Four new drugs were introduced in Portugal in 2012, one for macular degeneration, one for prostate cancer, another for colorectal cancer and lastly, one for preventing stroke in patients with atrial fibrillation. Besides these four new medicines, Bayer also launched two over the counter medicines in Portugal. These drugs, according to Nelson Ambrogio, were very important to sustain 2012’s results. “last year, Bayer Portugal had 158 million euros in profit, which represented a 5,4% decline compared to last year, but was not as large as in other companies, thanks to the new launches”.